IL-31 antibody
No associated image currently available
Rabbit anti Human Interleukin-31 antibody recognizes human IL-31 (interleukin-31), a 141 amino acid T-cell derived cytokine and member of the IL-6 cytokine family, which shares homology with oncostatin M, cardiotrophin-1 and LIF (leukaemia inhibitory factor).
.
IL-31 is preferentially produced by type 2 helper T cells (Th2) and signals through binding to the IL-31 receptor consisting of IL-31 receptor A (IL-31RA/GPL) and oncostatin M receptor B, activators of STAT1, STAT3 and STAT5. IL-31 is an important mediator of T cell mediated immune response and is particularly linked with diseases of the skin, including dermatitis and pruritic atopic skin inflammation, and is also implicated in bronchial inflammation.
.
IL-31 is preferentially produced by type 2 helper T cells (Th2) and signals through binding to the IL-31 receptor consisting of IL-31 receptor A (IL-31RA/GPL) and oncostatin M receptor B, activators of STAT1, STAT3 and STAT5. IL-31 is an important mediator of T cell mediated immune response and is particularly linked with diseases of the skin, including dermatitis and pruritic atopic skin inflammation, and is also implicated in bronchial inflammation.
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - lyophilised
- Reconstitution
- Reconstitute with 0.1ml distilled water.
For long term storage the addition of 0.09% sodium azide is recommended. - Antiserum Preparation
- Antisera to human IL-31 were raised by repeated immunisations of rabbits with highly purified antigen. Purified IgG was prepared by affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- None present
- Carrier Free
- Yes
- Immunogen
- Recombinant human IL-31.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
Storage Information
- Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at -20oC.
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of reconstitution.
More Information
- UniProt
- Q6EBC2
- Entrez Gene
- IL31
- GO Terms
- GO:0005125 cytokine activity
- GO:0005615 extracellular space
- Regulatory
- For research purposes only
Applications of IL-31 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | 0.5 | 2.0ug/ml | |
| Western Blotting | 0.1 | 0.2ug/ml |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Goat anti Rabbit IgG (Fc):Biotin | STAR121B | E WB | 1 mg |
|
|
| Goat anti Rabbit IgG (Fc):FITC | STAR121F | F | 1 mg |
|
|
| Goat anti Rabbit IgG (Fc):HRP | STAR121P | E WB | 1 mg |
|
|
| Goat anti Rabbit IgG (H/L):HRP | STAR124P | C E WB | 1 mg |
|
|
| Sheep anti Rabbit IgG:FITC | STAR34B | C F | 1 mg |
|
|
| Sheep anti Rabbit IgG:RPE | STAR35A | F | 1 ml |
|
|
| Sheep anti Rabbit IgG:DyLight®488 | STAR36D488GA | F IF WB | 0.1 mg | ||
| Sheep anti Rabbit IgG:DyLight®680 | STAR36D680GA | F IF WB | 0.1 mg | ||
| Sheep anti Rabbit IgG:Dylight®800 | STAR36D800GA | F IF WB | 0.1 mg |
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| TidyBlot Western Blot Detection Reagent:HRP | STAR209P | WB* | 0.5 ml |
Product Specific References
Further Reading
-
Castellani, M.L. et al. (2006) Interleukin-31: a new cytokine involved in inflammation of the skin.
Int J Immunopathol Pharmacol. 19 (1): 1-4.
